Eli Lilly’s crop of new products propelled the company to 8% sales growth in the fourth quarter, but the most pleasing aspect for the firm was likely the resilience of its diabetes blockbus
Danish pharma Novo Nordisk posted second-quarter operating profit in line with forecasts but hinted about the possibility of cutting the price of some drugs on the US market next year.
New phase 3b trial results show Lilly’s Trulicity combined with an SGLT2 inhibitor failed to show any benefits above and beyond Trulicity’s blood glucose lowering.
